课题基金 / 基金详情

Nanocarriers for delivery of antioxidants to endothelium

Nanocarriers for delivery of antioxidants to endothelium
用于将抗氧化剂递送至内皮的纳米载体
批准号:
6816060
负责人:
Vladimir R Muzykantov
金额:
$39.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-08-11 至 2008-04-30

项目摘要

项目成果

Vladimir R Muzykantov的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Vascular oxidant stress plays a key role in many pathologic states including hyperoxia, inflammation, ischemia, pulmonary and cardiovascular diseases. However, current antioxidant therapies are not effective, in part due to sub-optimal delivery to endothelial cells (EC). Previous studies have shown that the antioxidant enzyme (AOE) catalase (that detoxifies freely diffusing H2O2) conjugated with antibodies to endothelial Cell Adhesion Molecules (CAM) accumulates in EC after intravenous injection and protects animals against acute oxidant lung injury. Unfortunately, anti-CAM/AOE conjugates are eliminated from the blood and degraded in the EC within a few hours, affording only transient effects. In order to solve this problem and to achieve higher therapeutic duration and utility, we propose to load catalase into H2O2-permeable, anti-CAM targeted di-block PEG-PLGA Polymer Nano-Carriers (PNC) that would prolong the AOE circulation and protect from lysosomal proteolysis. Pilot data show that catalase loaded inside stealth anti-CAM/PNC degrades H2O2, binds to and protects EC from oxidant injury, circulates in animals for a prolonged time, and accumulates in the lung vasculature. The goal of this grant is to explore, test and optimize this strategy, pursuing the following Specific Aims: 1. Optimize the design of PNC for AOE delivery to EC. PEG-PLA PNC formulation, composition, size, AOE loading, activity and protease resistance, rate of pH-dependent degradation, coupling of anti-CAM, binding, uptake and metabolism by EC, and protection of EC will be studied and optimized in vitro. 2. Characterize the behavior and targeting of anti-CAM/PNC/AOE in vivo. Their blood clearance, systemic effects, biodistribution, EC binding, pulmonary targeting, optimal administration routes and persistence in lungs will be tested in naive animals and animals with oxidant vascular stress. 3. Evaluate the effects of anti-CAM/PNC/AOE in animals. Mouse models of acute H2O2 generation in the pulmonary vasculature and sub-acute oxidant stress in the lungs (hyperoxia) will be employed to evaluate the degree and duration of protection, and refine regimens of AOE targeting and mechanisms of protection. Completion of these Aims will be a major step towards the long-term goal of our research, which is translation of this promising new technology platform into the clinical domain.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1097/tp.0b013e318226bc6b
发表时间: 2011-08-27
期刊: Transplantation
影响因子: 6.2
作者: [Preissler G, Loehe F, Huff IV, Ebersberger U, Shuvaev VV, Bittmann I, Hermanns I, Kirkpatrick JC, Fischer K, Eichhorn ME, Winter H, Jauch KW, Albelda SM, Muzykantov VR, Wiewrodt R]
通讯作者: Wiewrodt R
Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates.
根据抗体 - 抗氧化剂酶结合的大小对内皮靶向的调节。
DOI: 10.1016/j.jconrel.2010.10.026
发表时间: 2011-02-10
期刊: Journal of controlled release : official journal of the Controlled Release Society
影响因子: --
作者: [Shuvaev VV, Tliba S, Pick J, Arguiri E, Christofidou-Solomidou M, Albelda SM, Muzykantov VR]
通讯作者: Muzykantov VR
DOI: 10.1016/j.freeradbiomed.2010.05.022
发表时间: 2010-08
期刊: Free radical biology & medicine
影响因子: 7.4
作者: [V. Muzykantov]
通讯作者: V. Muzykantov
BC-mediated delivery of thromboprophylaxis
  • 批准号:
    10277205
  • 项目类别:
  • 资助金额:
    $66.0万
  • 财政年份:
    2021
  • 负责人:
    Vladimir R Muzykantov
  • 依托单位:
Dual drug delivery to lung/blood interface in respiratory infections.
  • 批准号:
    10179690
  • 项目类别:
  • 资助金额:
    $74.23万
  • 财政年份:
    2021
  • 负责人:
    Vladimir R Muzykantov
  • 依托单位:
BC-mediated delivery of thromboprophylaxis
  • 批准号:
    10475755
  • 项目类别:
  • 资助金额:
    $66.66万
  • 财政年份:
    2021
  • 负责人:
    Vladimir R Muzykantov
  • 依托单位:
Dual drug delivery to lung/blood interface in respiratory infections.
  • 批准号:
    10614476
  • 项目类别:
  • 资助金额:
    $72.11万
  • 财政年份:
    2021
  • 负责人:
    Vladimir R Muzykantov
  • 依托单位:
海外基金